Discordant predictions of residual activity could impact dolutegravir prescription upon raltegravir failure

Dolutegravir may potentially be effective in the majority of HIV-1 patients failing raltegravir, but concern over the uncertainty in predicted residual activity could withhold clinicians from prescribing dolutegravir during its clinical assessment.